A strong regulatory strategy and successful regulatory engagements remain approaches companies can take to de-risk products for investors. Learn how you can leverage these to meet your milestones and goals in this complimentary, in-person discussion, including lunch and a tour of the CHTC facility

Establishing rapport and credibility with a regulatory agency, such as the US Food and Drug Administration (FDA), early in a life sciences company’s journey is a critical factor for its success. It will have an impact on the company’s ability to fundraise, meet milestones, meet budgets, and of course, make its product available to the patients and providers who need it.

Knowing when and how to engage with a regulatory agency to facilitate an ideal outcome is an art. The nuances and subtleties of which complicate an already ever-dynamic life sciences regulatory landscape. As a CEO or other executive, it’s important to have confidence that the regulatory strategy for your product is innovative and sound, and that when you meet with FDA you know what to say, when to say it, and who to bring. This is not only important for you, but also for your Board, your investors, your team, and your market.

Register